SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending amid community excitement over potential gains and a possible deviation from Bitcoin's price action. Discussions include speculation about an ETF, share buybacks, and the start of altcoin season. Some believe LTC is undervalued and poised for a significant breakout.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as traders discuss potential breakouts and Elon Musk's influence, while some express concerns about its long-term potential. Community members are actively debating technical indicators and the possibility of a pump, with some speculating on future price movements. The conversation also includes general sentiment around crypto and altcoins.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

Marathon Petroleum (MPC) is gaining attention as analysts update ratings and price targets, influenced by factors such as refining margins, potential mergers, and market conditions. Community discussions revolve around technical indicators, entry and exit strategies, and potential upside amid sector-wide movements. Several options alerts are highlighting call and put opportunities, reflecting varied sentiments around MPC's future performance.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as community members discuss its recent price surge and potential for further gains, with some eyeing $1000. The excitement seems linked to increased institutional interest, particularly the Winklevoss twins' investment via Cypherpunk Technologies ($CYPH), fueling speculation about ZEC's role as a privacy-focused alternative to Bitcoin.  Traders are actively debating entry points, potential targets, and whether this rally has staying power.

SPDR Series Trust - State Street SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Growth ETF

SPYG is trending due to discussions around ETF rotations, particularly between growth and dividend ETFs, and its performance relative to value and small-cap ETFs. Community members are weighing SPYG's growth potential against dividend-focused strategies and broader market trends. Recent large-cap growth strength has further fueled the conversation.

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Advanced Visualization Solutions segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare Technologies Inc

GEHC is trending as investors digest recent news, including potential undervaluation and upcoming conference presentations. The community is actively discussing its oversold RSI and potential for a bullish reversal, with some eyeing specific entry and target points. Bullish analysts point to Jeffries' upgrade while bears are taking a cautious view, citing valuation relative to sales.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around the potential release of Epstein files and their implications for Trump, with community members debating the validity and impact of these files. The stock's performance is also being scrutinized, with bearish sentiment fueled by low revenue, sustained losses, and reliance on Trump's name rather than business fundamentals. Some investors express concerns about potential insider selling and the company's long-term viability.

Wix.com Ltd. operates a cloud-based website design and development platform. It offers web templates, web editor, web builder, search engine optimization tools, logo maker, web hosting, and electronic mail marketing services. The company was founded by Avishai Abrahami, Nadav Abrahami, and Giora Kaplan on October 5, 2006, and is headquartered in Tel Aviv, Israel.

Wix.com Ltd

Wix is trending as the company's earnings approach, with community members weighing whether the stock is poised for a recovery or if they've gotten in too early. Bullish sentiment is fueled by strategic partnerships, AI-driven product discovery, and recent acquisitions, while others express concerns about market share and potential AI disruption to Wix's business model. Some traders note basing patterns and look for breakouts while also acknowledging potential resistance overhead.

BlockDAG

BlockDAG (BDAG) is trending amid discussions about its ongoing presale and future launch, with debates focusing on the project's legitimacy, extended presale timeline, and potential for returns. Community members are weighing the risks and opportunities, while also sharing referral codes for the BlockDAG X1 mining app. Partnerships with Formula 1 teams and listings on crypto exchanges are adding to the buzz.

Kinder Morgan, Inc. engages in providing pipeline transportation of natural gas services. It operates through the following business segments: Natural Gas Pipelines, Products Pipelines, Terminals, and CO2. The Natural Gas Pipelines segment operates major interstate and intrastate natural gas pipelines and storage systems. The Products Pipelines segment is involved in the operation of refined petroleum products, crude oil, and condensate pipelines. The Terminals segment includes the operation of liquids and bulk terminal facilities that store and handle various commodities. The CO2 segment produces, transports, and markets to oil fields that use CO2 as a flooding medium to increase recovery and production of crude oil from mature oil fields. The company was founded by Richard D. Kinder and William V. Morgan in February 1997 and is headquartered in Houston, TX.

Kinder Morgan Inc - Ordinary Shares - Class P

Kinder Morgan is trending amid analyst upgrades and discussions around its potential to benefit from increased natural gas demand, particularly from AI data centers. Community members are weighing KMI against competitors, focusing on dividend stability and growth prospects. The stock's recent performance and infrastructure projects are also key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Scholar Rock Holding Stock Climbing Today?

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.read more...

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Scholar Rock Soar 26% Today?

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 

Equity

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee...

Scholar Rock (SRRK) to Release Earnings on Friday

Scholar Rock (NASDAQ:SRRK) will be releasing its Q3 2025 earnings before the market opens on Friday, November 14. (View Earnings Report at...

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open. Following the release of the...

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and...

A Canaccord analyst on Monday highlighted the risks associated with the U.S. Food and Drug Administration’s ‘Official Action Indicated’ designation on Catalent Indiana LLC, a third-party fill-finish facility.Novo Nordisk's (NVO) update that the FDA has classified Catalent Indiana LLC as "Official Action Indicated" raises the risk of further delay for Regeneron’s (REGN) Eylea HD prefilled syringes, as they are produced at the same site, the analyst noted. Catalent Indiana was acquired by Novo Nordisk (NVO) in December.Notably, Regeneron had <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">said</a> in August that the FDA extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions until the fourth quarter, owing to issues identified at the fill-finish facility.Regeneron is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-in-spotlight-after-fda-refuses-to-approve-muscular-atrophy-treatment/chDhUSIR35Z">refused</a> to approve Scholar Rock’s (SRRK) Apitegromab drug for the treatment of patients with spinal muscular atrophy over concerns identified during the inspection of Catalent Indiana's facility.Breaches at Catalent Indiana’s facility have been classified as "Official Action Indicated," Scholar Rock said in a statement. The serious designation means regulatory and/or administrative actions are recommended to resolve the concerns identified.Scholar Rock said that it continues to work closely with Novo and has requested a meeting with the FDA to discuss the next steps for resubmitting its Apitegromab drug application.While REGN shares traded 2% lower at the time of writing, <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> fell 12%. While retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, sentiment around SRRK rose from ‘neutral’ to ‘bullish’ territory.<figure class="image"><img style="aspect-ratio:620/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_20_48_PM_png_df71d2ade1.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="620" height="61"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_21_27_PM_png_5e9ad0811c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="623" height="63"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>SRRK stock has dropped about 20% this year, while REGN lost 22%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-approves-changed-recommendations-for-use-of-abbvie-rinvoq/ch6SFlFR3lG">AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Are Regeneron And Scholar Rock Shares Falling On Monday?

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 

Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRRK News

SRRKScholar Rock Holding Corp